RORγt inverse agonist 14 (8e) is a potent, selective, and orally active compound with an EC50 of 2.5 nM, demonstrating anti-inflammatory activity. It is utilized in the research of rheumatoid arthritis and psoriasis [1].

RORγt inverse agonist 14 (8e) exhibits a half-life (t 1/2) of 11 hours following intravenous (iv) injection at 1 mg/kg. When administered orally at 4 mg/kg in mice, the compound achieves a peak concentration (t max) in 2 hours, with an oral bioavailability (%F) of 101 [1]. Additionally, dosages ranging from 5 to 20 mg/kg effectively reduce arthritic scores, comparable to the murine analog of the commercially available TNF decoy receptor, etanercept [1].